Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic resistance crisis: so bad, it's good?

This article was originally published in Scrip

Executive Summary

Around 25,000 people in the EU (including 5,000 children) and 23,000 in the US die each year as a direct result of infections from resistant bacteria, according to estimates by the US Centers for Disease Control and Prevention (CDC) and the European Commission. With the dearth of new antibiotics coming through industry pipelines, it seems likely that these numbers will rise. According to Dr Neil Murray, CEO of Redx Pharma (which has an anti-infectives subsidiary focused on developing new compounds for resistant bacteria), this bad news has a silver lining.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel